WEHI (Walter and Eliza Hall Institute of Medical Research)’s Post

Today marks a paradigm shift in the monitoring of #Type1diabetes (T1D). Our organisation, along with 60 international experts & 10 diabetes orgs, published new T1D monitoring guidance for health care professionals. Research has shown that the condition can exist without symptoms for months or years as early-stage T1D, before it is traditionally diagnosed. Until now, there was no standard advice on how to detect, follow up, or support people with early-stage T1D. For the first time, individuals, families, and healthcare professionals now have concrete guidance how to diagnose early-stage T1D, monitor progression of the condition, catch symptoms early to prevent diabetic ketoacidosis and identify those eligible for clinical trials. The guidance document was co-authored by JDRF-funded Australian researchers Jennifer Couper, Maria Craig, Kirstie Bell, John Wentworth and endorsed by the Australian Diabetes Society. Learn more on our website: https://jdrf.news/8i8 Breakthrough T1D, Charles Perkins Centre, University of Adelaide, The Royal Melbourne Hospital, WEHI (Walter and Eliza Hall Institute of Medical Research), UNSW Medicine & Health Anastasia Albanese-O'Neill, Sanjoy Dutta, Moshe Phillip, Linda DiMeglio

Remote teams focused on identifying, educating, and prescribing therapy can improve guideline-directed-medical-therapy adherence in patients with type 2 diabetes and high cardiovascular and/or kidney risk, according to a Mass General Brigham study. That research aligns with the fact that patients who take part in a Diabetes Self-Management Education and Support (DSMES) program like My Diabetes Tutor (MDT) improve their A1C scores, LDL, triglycerides, etc. It’s why DSMES programs are recommended by the American Diabetes Association, the AMA, and the CDC. Find out how MDT can be part of your patient's diabetes care team and help improve health outcomes: https://buff.ly/3sf9m28 #diabetes #diabeteseducation #diabetespatientmanagement

The CDE Academy reminds you to register for our January Journal Club! Date: Tuesday, 23rd January 2024 Time: 19h30 - 20h30 Specialist Physician, Dr Angela Murphy will join Dr Stan Landau as our expert guest for this month’s discussion. They will discuss the relevance of diabetes guidelines in providing a more systematic and safer evidence-based framework for decision making in comprehensive diabetes management. While diabetes guidelines are valuable, it’s essential to recognise that they will always evolve over time based on new information, societal expectations and advancements in knowledge and insight. It is thus important to critically evaluate guidelines like the annually updated American Diabetes Association Standards of Care Remember, each session is FREE of charge, presented LIVE in real-time, and is CPD-accredited. Secure your e-seat today: https://lnkd.in/gTXnPjgT #diabetesguidelines #diabetesmanagement #continuingeducation #journalclub #CDEAcademyJournalClub #January2024 #CDEVirtualEvent #diabeteseducation #diabetesawareness

Type 1 diabetes remission and prevention have been hot topics in the last few years. To thus be able to guest co-host a The Royal Australasian College of Physicians' Pomegranate Journal Club episode on this topic was very exciting. Mic and I got to interview Michelle So and Jenny Couper on their paper published in NEJM on baricitinib immune therapy for new onset type 1 diabetes. You can listen to the episode online or read the transcript here: https://lnkd.in/ge44F8Et #diabetes #T1D #prevention #immunomodulation

Did you know that #cardiovasculardisease remains the leading cause of death in the United States? Here are some tips your cardiologists wants you to know. Click on the numbered statements for additional information and see the comments for #IUKrannertHeart clinical trials. https://lnkd.in/g5aRqgnc #lifestylechoices #hearthealth #heartdisease #iukrannertheart

Healthcare leaders can take action to address a rising risk in #cardiovasculardisease rates. The UpToDate Point of Care Report reveals how enterprises can lead in #HeartHealth, emphasizing empathic engagement and education. Download the report to gain strategies for improving cardiovascular care. https://lnkd.in/g2xA8Xdk #CVD

Did you know that the top 3 medical conditions that will drive medical plan costs in 2024 are cancer, cardiovascular disease and high blood pressure? That’s according to Aon’s 2024 Global Medical Trend Rates Report, published this week.   The report also predicts that the global average medical trend rate will reach 10.1% in 2024, up from 9.2% in 2023 – and the highest rate since 2015.   If you’d like to learn what other conditions are contributing to rising medical costs, and what action your company can take to manage them, why not download the report? There’s a link to it in the comments section.   Thanks to everyone in Aon's Health Solutions for their hard work in producing this essential piece of research!   #Healthcare #HealthcareCosts #MedicalTrends #MedicalConditions 

Accessing affordable healthcare in Vietnam is no longer a difficult task. With healthcare costs ranging to fit any budget, basic medical conditions can be treated without putting a dent in your wallet. However, it is crucial to keep in mind that minor medical conditions can develop and lead to serious illnesses such as cancer and cardiovascular diseases. Thankfully, annual health screenings are mandatory for corporate employees by law in Vietnam. As a healthcare innovation solution provider, we believe in providing continuous care and risk management for both physical and mental health. Annual health screenings are not a one-time service, but a crucial step towards ensuring long-term well-being. To learn more about the latest global medical trend rates, refer to the #2024GlobalMedicalTrendRatesReport. We would like to extend our gratitude to #AonHealthSolutions for their commendable work. #Vietnammarkettrend #Vietnamhealthsolutions #Asiadigitalhealth #HealsClinic #HealsAsia #MyDoc #MentalWellness #WorldMentalHealthDay

Semaglutide is making waves in the medical world with its versatility and groundbreaking benefits. The medication is effective in treating conditions like obesity, type II diabetes, NASH, heart failure, and cardiovascular disease. Its significant impact on symptom reduction and improved health outcomes is drawing attention and creating much anticipation. However, the deployment of this ‘wonder drug’ is not without its challenges, especially in the realms of economics and policy. With questions arising around the viability of health plan coverages, the unfolding scenario is generating discussions and debates. Will long-term plans like Medicare embrace it fully, realizing its extensive benefits? And what does it mean for private health plans where members may leave the health plan within one year? Stay tuned for my upcoming article tomorrow, where I delve deep into the medical marvel that is semaglutide and explore the intricate economic and policy enigmas it unfolds. Subscribe to Healthcare Huddle here to read it tomorrow: [https://lnkd.in/dkznFNR3]

In the next 3 years, over 16,000 people in England will suffer highly preventable heart attacks and strokes because their blood pressure or cholesterol is not being treated optimally. One in 3 people with high blood pressure are not treated to target and one in 6 people with cardiovascular disease are not on essential cholesterol lowering therapy. See UCLPartners Size of the Prize for every Integrated Care Board.   How can we support GP teams to transform management of these and other high risk conditions when primary care is under huge pressure? At #HETTNorth24, Laura Boyd and I will update on the exciting new CVDACTION programme underway in PCNs across England. The CVDACTION smart data tool identifies patients who are on suboptimal treatment for single or multiple high risk conditions, helps prioritise and create manageable chunks of work to assist workflow across the team, and allows clinicians to target health inequalities.   Good data is critical to transforming care and outcomes - but it is not enough. We will discuss how the CVDACTION demonstrator programme brings together data, workforce, lived experience and practical implementation support - to enable primary care teams to do things differently in the real world, and prevent heart attacks and strokes at scale.